Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) just unveiled an update.
Hemogenyx Pharmaceuticals plc has issued 123,377 new ordinary shares following warrant exercises, restricted stock unit vesting, and obligations under a Deed of Variation. This issuance, raising £190,000 and leading to adjustments in total issued shares and voting rights, reflects the company’s ongoing efforts to fund operational developments and ensure alignment with regulatory requirements, which may strengthen its market positioning and reassure stakeholders.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals plc is a publicly listed biopharmaceutical company based in London, with operational subsidiaries in New York City. The company specializes in developing innovative treatments for blood and autoimmune diseases, using both its unique platform technologies and a pipeline of product candidates.
Average Trading Volume: 54,350
Technical Sentiment Signal: Buy
Current Market Cap: £37.05M
See more insights into HEMO stock on TipRanks’ Stock Analysis page.